GSA Finalizes Rule Declaring Certain Commercial Supplier Agreement Terms Unenforceable
Client Alert | 1 min read | 02.26.18
On February 22, 2018, GSA published a final rule amending its acquisition regulation and declaring certain common Commercial Supplier Agreement (CSA) terms—such as indemnification and arbitration provisions, provisions that subject the U.S. Government to state law, and automatic renewal provisions—unenforceable in government contracts as inconsistent with federal procurement law. GSA published the proposed rule in June 2016 (discussed here) and related class deviation (discussed here) in August 2015.
The final rule makes several noteworthy changes to GSA’s proposed rule, including: (1) it reverts the order of precedence of contract terms to give precedence to “[a]ddenda to [the] solicitation or contract, including any commercial supplier agreements as amended by the Commercial Supplier Agreements—Unenforceable Clauses provision” over “[s]olicitation provisions” and “[o]ther paragraphs of [the] clause”; and (2) it removes the previously proposed requirement to provide full text CSA terms with the offer, paving the way for CSA terms to be incorporated by reference. As GSA maintains, this final rule will eliminate the need for negotiation on the identified unenforceable terms and could facilitate faster procurements.
Contacts
Partner
She/Her/Hers
Partner
She/Her/Hers
Insights
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
As reported in an earlier Client Alert, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In the letters, the FTC indicated it is using the FDA’s regulatory dispute process to challenge the listing of these patents in the Orange Book because improperly listed patents may violate antitrust laws and impede competition.
Client Alert | 3 min read | 04.26.24
CFIUS Proposes Enhanced Enforcement and Mitigation Rules and Steeper Penalties for Non-Compliance
Client Alert | 3 min read | 04.25.24
JUST RELEASED: EPA’s Bold New Strategic Civil-Criminal Enforcement Collaboration Policy
Client Alert | 6 min read | 04.25.24
